Background: Repeat cervical mediastinoscopy is a diagnostic surgical procedure for preoperative nodal staging in patients with insufficient first mediastinoscopy, with recurrent or second primary lung neoplasms, and following induction chemotherapy or chemo−/radiotherapy for locally advanced lung cancer. The aim of this study was to critically analyse indications, technical characteristics, intra− and postoperative complications, also to define selection criteria for patients with a higher probability of successful complete resection. Material and methods: 279 pa− tients with lung cancer (66 female and 213 male patients, mean age 58 years, range 28 to 78 years) underwent repeat mediasti− noscopy from 1968 to 2004, 12 because of inadequate first proce− dure (group A), 67 because of recurrent lung cancer (group B) 35 because of second primary lung cancer (group C), and 165 fol− lowing induction chemo−/radiotherapy for IIIa and IIIb disease (group D). The interval between first and second procedure was 17 days (range, 12 ± 38) in group A, 14 months (range, 5 ± 29) in group B, 27 months (range, 19 ± 124) in group C, and 132 days (range, 113 ± 145) in group D. Results: No intra− or postoperative deaths were observed, 7 patients developed minor complica− tions. N2 or N3 disease was found in 3/12 patients of group A (25 %), in 17/67 patients of group B (25.4 %) and in 6/35 patients of group C (17.1 %). Of the 116 patients with N2, and 49 with N3 disease before induction treatment (group D), repeat mediasti− noscopy showed 126 N0, 20 N2 and 14 N3 status. Because of the presence of inseparable adhesions repeat mediastinoscopy was not possible in 5 cases. Five−year survival for patients with per− Zusammenfassung Einleitung: Die kollare Remediastinoskopie stellt ein diagnosti− sches Verfahren zur Klärung des Lymphknotenstatus bei Patien− ten mit Bronchialkarzinom und einer insuffizienten ersten Me− diastinoskopie, beim Lokalrezidiv, beim Zweittumor und schließlich nach neoadjuvanter Chemotherapie oder Chemo−/ Radiotherapie beim lokal fortgeschrittenen Bronchialkarzinom dar. Ziel dieser aggressiven erneuten Untersuchung des oberen Mediastinums ist die Selektion von Patienten mit einer höheren Wahrscheinlichkeit einer kurativen Resektion. Krankengut: Von 1968 ± 2004 wurde bei 279 Patienten mit einem Bronchialkarzi− nom eine Remediastinoskopie vorgenommen, 12 wegen einer nicht aussagereichenden ersten Mediastinoskopie (Gruppe A), 67 wegen eines Lokalrezidivs nach vorausgegangener Resektion (Gruppe B), 35 wegen eines Zweittumors (Gruppe C) und schließlich 165 nach induktiver Chemo−/Radiotherapie für Bron− chialkarzinom im Stadium IIIA und IIIB (Gruppe D). Es handelte sich um 66 Frauen und 213 Männer mit einem Durchschnittsal− ter von 58 Jahren (28 ± 78 Jahre). Das Zeitintervall zwischen der ersten und zweiten Untersuchung betrug für die Gruppe A 17 Tage (12 ± 38), die Gruppe B 14 Monate (5 ± 29), die Gruppe C 27 Monate (19 ± 124) und die Gruppe D 132 Tage (113 ± 145). Ergeb− nisse: Die intra− oder postoperative Letalität betrug 0 %. Bei 7 Pa− tienten konnten leichte Komplikationen festgestellt werden. Bei der Remediastinoskopie fand sich in 3/12 Fällen der Gruppe A (25 %), in 17/67 der Gruppe B (25,4 %) und in 6/35 der Gruppe C (17,1 %) eine N2− bzw. N3−Situation. In der Gruppe D hatten vor der Induktionstherapie 116 Patienten eine N2− und 49 eine Original Article 862
Introduction
Preoperative evaluation of the mediastinal lymph nodes is im− portant in patients with lung cancer in order to determine local operabiliy and/or need for neoadjuvant treatment. Cervical me− diastinoscopy (CM) is generally accepted as a safe and highly ac− curate procedure in the staging of lung cancer. Nodes accessible to CM are those of the superior (level 2R and 2L) and inferior (level 4R and 4L) paratracheal and subcarinal (level 7) nodal sta− tions. Additionally, extended CM and left parasternal mediasti− notomy allow exploration of the aortopulmonary window (level 5) and anterior mediastinal nodes (level 6). Until the early nine− ties, repeat mediastinoscopy (RM) was considered contraindica− ted because of fibrosis due to the first procedure and the associa− ted risk of injury to vital structures [1 ± 3] . Neoadjuvant clinical trials with induction chemotherapy or chemoradiation, however, necessitated agressive re−exploration of the upper mediastinum. Prognostically, it seemed important to select therapy−responsive patients with high probability of complete resectability, thereby reducing the number of futile thoracotomies in patients with lo− cally advanced lung cancer [4 ± 6] . Early studies included small numbers of patients, but demonstrated technical feasibility and high diagnostic accuracy. Further indications were reported in patients after insufficient first mediastinoscopy and for staging of recurrent or second primary lung neoplasms [7 ± 10] .
The aim of this study was to present the large experience of our institution with this method, and to critically analyse indica− tions, technical characteristics, intra− and postoperative compli− cations, finally to define groups with high probability of comple− te resectability after multimodal treatment and prognostically higher survival.
Material and methods
From 1961 to 2004 we performed more than 22 800 CM in all pa− tients with suspected or previously diagnosed lung cancer. 279 patients (66 female and 213 male patients, mean age 58 years, range, 28 ± 78 years) underwent RM (1.17 %). The indication for RM were inadequate first procedure (group A), defined as com− plete absence of lymphatic tissue on biopsies or biopsies that had not sampled contralateral nodal stations, recurrent disease following prior resection for non small cell carcinoma (group B), preoperative staging for second primary lung cancer, defined as second malignancy with a different histologic type, different anatomic site and occurrence after more than 2 years from the first malignancy (group C), and RM following induction chemo−/ radiotherapy for NSCLC IIIa−IIIb and SCLC IIb−IIIb disease (group D). There were 12 patients in group A, 67 in group B (16 with prior stage IB, 12 stage IIA, 32 stage IIB and 7 IIIA disease, they had resulted in 47 lobectomies, 8 bilobectomies and 12 sleeve lobectomies), 35 patients in group C (prior resection included 28 lobectomies, 3 bilobectomies and 4 sleeve lobectomies), and 165 in group D (N2, 165 patients and N3, 49 patients). Neoadju− vant treatment in group D consisted of 3 courses of chemother− apy (three cycles of split−dose cisplatin 60 mg/m 2 days 1,7 and etoposide 150 mg/m 2 days 3, 4, 5) followed by concurrent che− moradiotherapy (one cycle cisplatin 50 mg/m 2 days 2, 9 and eto− poside 100 mg/m 2 days 4, 5, 6 combined with 45 Gy hyper− fractionated accelerated radiotherapy to primary tumor and mediastinal nodes) and restaging with CT scan of the chest and upper abdomen, CT of the brain, bone scan and bronchoscopy. Patients with radiological evidence of tumor remission or stable disease and Karnowsky index of more than 70 % underwent RM.
The interval between first and second procedure is demonstrated in table 1. RM was performed with resection of the scar of the first operation and preparation to the pretracheal fascia. Digital dissection and/or sharp preparation was followed by removal of adhesions along the "mediastinoscopic route". In case of severe fibrosis, the left paratracheal route was taken, an area generally relatively spared by the first mediastinoscopy. All accessible lymph nodes were sampled and mapped according to the revised regional lymph node classification for lung cancer by Mountain [11] . A RM was considered complete if bilateral inferior paratra− cheal (level 4R and 4L) and subcarinal (level 7) nodal stations were included. sistent N2 in repeat mediastinoscopy was despite surgery only 5 %. Conclusion: Repeat mediastinoscopy is a safe explorative procedure for the restaging of patients with primary locally ad− vanced, recurrent or second primary lung cancer. In patients af− ter induction treatment it is, however, less sensitive than the pri− mary mediastinoscopy because of adhesions and fibrotic tissue. Patients with persistent N2 or N3 disease in repeat mediastinos− copy have a poor survival so that the indication for surgery has to be taken into consideration very carefully. 
Results
No intra− or postoperative deaths were observed, average blood loss amounted to 26 ml (range 10 ± 160 ml) and was not different from first operation. Three patients developed postoperative re− currens nerve palsy, two had wound infection, two cardiac ar− rhythmia. RM was incomplete (14 patients, 5.2 %) or not possible (5 patients, 1.8 %) because of diffuse inseparable adhesions. Data of all patients with RM are demonstrated in the table 1. Diffe− rences in each group are described separately.
Group A. One patient with solitary nodal involvement (nodal sta− tion 4R) and all 9 patients with negative histology underwent re− sective surgery ( Group D. 116 patients had N2 and 49 N3 disease before induction treatment. The most frequent histological types were squamous cell carcinoma (59 patients) and adenocarcinoma (55 patients). They were followed by large cell carcinoma (19 patients), small cell carcinoma (28 patients) and mixed type of lung cancer (4 pa− tients) cases. RM was not possible in 5 cases because of the difu− se inseparable adhesions. A total of 528 lymph node stations (mean, 3.3) were sampled during 160 RM (compared to 672 no− dal stations at first mediastinoscopy, mean 4.2). The histological findings of RM demonstrated 126 N0, 20 N2 and in 14 N3 status. 27 patients with N3 and multilocular N2 disease, 2 patients with limited cardiopulmonary reserve, and one patient with cerebral metastasis were excluded from resection. One patient refused operative treatment. Resection in the remaining 129 patients yielded N0/N1 in 110 and N2/N3 in 19 cases status. 12 patients demonstrated N2 nodal involvement at thoracotomy that had not been evident at RM (false negative RM). For the group IV sen− sivity was 74 %, specifity 100 %, PPV 100 %, NPV 86 % and accuracy 92.5 %. Median survival rates in patients with persistent N2/N3 disease in RM was 17.8 months, in responders without nodal in− volvement 55.6 months. The five years survival was 5 % and 36.6 % respectively.
Discussion
46 years after its introduction by Carlens in 1959 [12] , mediasti− noscopy continues to be an important step in the evaluation of the mediastinal lymph node status and selection of patients with lung cancer for surgery. Depending on surgical technique, mediastinal exploration is varably described as cervical media− stinoscopy, parasternal mediastinotomy, extended cervical me− diastinoscopy and thoracoscopy. The results of prior studies sup− port routine use of mediastinoscopy in the preoperative staging of patients with lung cancer [13, 14] . RM, by contrast, was rare in the era before neoadjuvant treatment protocols of locally ad− vanced lung cancer. Patient numbers reported were small and outcome data was insufficient [1 ± 3] . RM was considered techni− cally difficult due to commonly encountered tissue adhesions and fibrosis, particularly between trachea and innominate arte− ry. Maaßen in 1968 performed the first RM at our institution in a patient with recurrent lung cancer. Meersschaut et al. was the first to employ RM as a routine staging procedure [7] . In his se− ries of 140 RMs he observed no procedural deaths and no compli− cations necessitating surgical revision. Indications for RM have since expanded to include incomplete primary mediastinoscopy [9] , assessment of locoregional extent of recurrent [2, 7, 9] and second primary cancer [8] , and re−staging after neoadjuvant che− motherapy [4 ± 6] . The present study, in addition, includes for the first time a large group of 165 patients post neoadjuvant chemo− radiation therapy.
The technical aspects of RM have been described in previous re− ports [4, 7] . The presence of peritracheal adhesions makes the ex− ploration more complex than at initial mediastinoscopy. We found that preparetion along the left lateral tracheal wall was simpler, possibly because of relative sparing during the first pro− cedure, and helped avoid the critical innominate−tracheal area. Digital dissection and direct sharp dissection or electrocautery was used for mediastinal exploration. Only 5 patients proved in− operable due to inseperable adhesions, beginning by the separa− tion of the strap neck muscles. In our opinion the feasibility of RM depends on exploration standards by the initial mediastinos− copy and the experience of the surgeon. If possible, biopsies have to be taken from the same nodal stations as at the first procedure and RM has to be done by the same surgeon. RM was performed 3 to 4 weeks after radiation therapy and was no more difficult than for other indications. Patients, however, were excluded from RM if radiation dose exceeded 45 Gy or if primary mediasti− noscopy was performed at another institution. Although our ex− perience with videoscopic RM is very limited, we think that the magnification of the optical field and the simultaneously use of more than one instrument may contribute to facilitate the prepa− ration.
The advent of new imaging techniques such computed tomogra− phy (CT scan) and magnetic resonance imaging (MRI) warrant a critical appraisal of mediastinoscopy today [15, 16] [17, 18] . FDG−PET results have been shown to be difficult to interpret after radiotherapy. An inherent prob− lem of the FDG contrast is that inflamed tissue will absorb it, so that granulomatous or inflammatory mediastinal disease or ca− ses of obstructive malignant processes result in difficulty to identify mediastinal malignancy. Radiated mediastinal tissue shows intense FDG uptake, accounting for 20 % false positive re− sults [19] . Only low uptake values, therefore, because of good ne− gative predictive accuracy, may obviate the need for RM [20] . The best time of study nevertheless remains undetermined.
EBUS and EUS guided FNA are additional new techniques em− ployed in the staging of solid tumors. They target lesions and lymph nodes adjacent to trachea, main bronchi and esophagus. Results, however, are not comparable to those of mediastinosco− py or RM [21, 22] , Selection of the patients for EUS or EBUS−FNA is based on computed tomographic scanning and with that done only in patients with pathological radiological findings [23] . Both techniques are used to assess the entire mediastinum or to stage predominantly only one nodal station, but they are not used for the systematical standarized exploration of individual nodes as performed by mediastinoscopy [24] . Moreover, the echogenic characteristics alone of a node might not be as reliable after radiation as they are before. In our experience it is difficult to obtain representative material from scarred lymph nodes after chemoradiotherapy and the false positive results on cytologic examination of FNA must be considered. The representative his− tological tissue, however, is because of the prognostic value para− mount in the assessment of locally advanced disease following induction therapy, so that it is unlikely that the addition of trans− tracheal, transbronchial, and endoscopic ultrasonographically guided FNA will sufficiently rule out disease relative to the histo− logic results achieved from mediastinoscopy. EBUS and EUS are supplementary diagnostical tools and may contribute to improve staging, especially in cases with metastasis in the hilar nodes or the mediastinal nodes which could not be reached by CM or RM.
Insufficient primary mediastinoscopy is uncommon today be− cause of better education of thoracic surgeons and introduction of procedural standards in departments with high activity in tho− racic surgery. Indeed, our study included only 12 cases of nega− tive primary mediastinoscopies, which, because of CT criteria or absence of bioptic lymph node tissue underwent RM at our insti− tution. RM was technically unproblematic, yielded 3 cases of N2 /N3 disease, and resulted in exclusion from surgery of 2 patients. In patients with recurrent or second primary cancer mediastinal lymph nodes sampling and not a systematic lymphadenectomy including the surrounding fat tissue was performed at the first operation. Despite considerable scarring, RM achieved accepta− ble sampling of nodal stations and directly contributed to suc− cessful resection in 41 patients with recurrent and 28 patients with second primary lung cancer. Futile thoracotomy was thus avoided in 14 cases of recurrent and 4 cases of second primary lung cancer, particularly when extracapsular or multilocal nodal involvement was detected.
Inclusion of systemic treatment as early as possible into the management of locally advanced non small cell lung cancer has proved feasible and effective, resulting in increased survival of stage IIIa and IIIb lung cancer patients in prospectively rando− mised trials [25, 26] . Several investigators have focused on early intensification of preoperative downstaging by bimodality induction including chemotherapy as well as radiation before surgery [27 ± 29] [31] . These data support surgical resection only for downstaged patients, mandating that every effort be made to improve the ac− curacy of restaging procedures. Indeed, both phase II and phase III trials completed by our oncology group [32, 33] included RM in their standard post−induction and pre−resective re−staging protocol. The total number of sampled stations at RM was slight− ly less compared to that at first mediastinoscopy (528 versus 672), indicating that not all lymph nodes were re−explored, mostly because of adhesions or fibrosis following the induction treatment. RM proved highly sensitive in identification of pa− tients with persistent N3 or multilocular N2 disease and thus was decisive in excluding prognostically inoperable patients from resective surgery. Incomplete eradication of mediastinal cancer post induction chemoradiation, however, was found in 26 % of patients. This resulted in a significant difference in me− dian survival and in 5 years survival between patients with posi− tive and negative RM. Because of the poor survival we decided to exclude patients with persistent N2/N3 disease at the RM from surgery.
We also found a small group of patients with N2 disease on pri− mary mediastinoscopy but negative cancer histology on RM that proved to have residual cancer on mediastinal lymphadectomy obtained during resective surgery. Such patients have previously been thought to have an inherently better prognosis [4] , an as− sumption not born out in our patient's series.
We conclude that RM is a feasible and safe surgical procedure for the restaging of patients with primary locally advanced, recur− rent or second primary lung cancer. Mortality is nil and periope− rative complications are rare. Diagnostic accuracy outweighs that of radiological staging studies (including chest CT scan and MRI), FDG−PET and ultrasound guided FNA, and remains high even in the setting of tissue fibrosis post induction radio−chemo− therapy. RM, therefore, must be considered despite the technical complexity as criterion standard for mediastinal restaging in pa− tients with locally advanced lung cancer and following neoadju− vant induction treatment.
